United Therapeutics Corporation Stock News

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before

The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.

With so much attention paid to artificial intelligence and cryptocurrencies, the risk-on segment of the global markets has enjoyed tremendous upside, which subsequently makes the search for bargain st

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Growth-oriented and patient investors love undervalued NASDAQ stocks to sink their teeth into. Despite current low prices, undervalued stocks present the opportunity to reap the benefits of future gro

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment oppor

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

The consensus price target hints at a 32.7% upside potential for United Therapeutics (UTHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall

United Therapeutics said on Wednesday it has commenced litigation with the U.S. FDA for allowing an application for a drug by Liquidia Corp to treat a type of blood vessel disorder.